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 No differences in host survival were observed in mixed T. cruzi infected hosts 
 Spontaneous deaths were observed following T. cruzi reinfection 
 Compared to single infections, reinfection significantly increased mortality rate 
 Reinfection was associated with a significant reduction in host survivability 
Abstract 
The progression of Chagas disease (CD) varies significantly from host to host and is affected 
by multiple factors. In particular, mixed strain infections and reinfections have the potential 
to exacerbate disease progression subsequently affecting clinical management of patients 
with CD. Consequently, an associated reduction in therapeutic intervention and poor 
prognosis may occur due to this exacerbated disease state. 
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This study investigated the effects of mixed strain infections and reinfection with 
Trypanosoma cruzi in mice, using two isolates from different discrete typing units, TcI (C8 
clone 1) and TcIV (10R26). There were no significant differences in mortality rate, body 
weight or body condition among mice infected with either C8 clone 1, 10R26, or a mixture 
of both isolates. However, the parasite was found in a significantly greater number of host 
organs in mice infected with a mixture of isolates, and the histopathological response to 
infection was significantly greater in mice infected with C8 clone 1 alone, and C8 clone 1 + 
10R26 mixed infections than in mice infected with 10R26 alone. 
To investigate the effects of reinfection, mice received either a double exposure to C8 clone 
1; a double exposure to 10R26; exposure to C8 clone 1 followed by 10R26; or exposure to 
10R26 followed by C8 clone 1. Compared to single infection groups, mortality was 
significantly increased, while survival time, body weight and body condition were all 
significantly decreased across all reinfection groups, with no significant differences among 
these groups. The mortality rate over all reinfection groups was 63.6%, compared to 0% in 
single infection groups, however there was no evidence of a greater histopathological 
response to infection. 
These results suggest firstly, that the C8 clone 1 isolate is more virulent than the 10R26 
isolate, and secondly, that a more disseminated infection may occur with a mixture of 
isolates than with single isolates, although there is no evidence that mixed infections have a 
greater pathological effect. By contrast, reinfections do have major effects on host 
survivability and thus disease outcome. This confirms previous research demonstrating 
spontaneous deaths following reinfection, a phenomenon that to our knowledge has only 
been reported once before. 
1.1 Introduction 
Chagas Disease (CD) is a zoonotic disease of global significance, caused by infection with 
Trypanosoma cruzi. CD commonly occurs in humans and dogs, with various other 
mammalian and non-mammalian species acting as reservoir hosts [1, 2]. Global migration 
has resulted in the spread of infection, with increasing numbers of infected individuals 
migrating worldwide to countries non-endemic for CD [3, 4]. Historically, the global spread 
of T. cruzi transmission has been restricted by the lack of insect vectors in areas non-
endemic for disease. However, there is now evidence to suggest that vectors capable of T. 
cruzi transmission may exist within these areas [2, 5-7]. 
Within endemic areas, vector borne transmission remains the central mode of infection, 
with more than 80% of disease attributable to vectorial transmission [8] and more than 40% 
of sampled vectors across South America reported to be infected with T. cruzi [9, 10]. The 
domestication of triatomines, the style of housing [11] and proximity to henhouses, pigsties 
and animal pens, in combination with poor food hygiene, all lead to an increased risk of 
vectorial transmission [12]. The feeding habits of vectors within areas endemic for CD, 
whether that be on infected or naïve hosts, also affect the risk of host re-exposure and thus 
the rate of reinfection or super-infection (infection on more than one occasion) [13] and 
mixed infections or polyparasitism (infection with more than one genotype of the parasite) 
[14]. 
T. cruzi is genetically highly heterogeneous [15], with isolates classified into discrete typing 
units (DTUs) TcI through to TcVI. These classifications are based on genetic, biological and 
ecological characteristics, with specific correlations existing between geographical 
distributions and sylvatic or domestic transmission cycles [16]. The circulation of genetically 
different forms of T. cruzi within vector populations [17] means that there is likely to be a 
complex interaction between reinfection and mixed infections, as there are various 
scenarios where hosts may encounter T. cruzi genotypes. For example, if we consider 
infections with up to two different T. cruzi genotypes, a host may encounter a single 
infection with one genotype as the result of a bite from one singly infected vector; a mixed 
infection with two genotypes as the result of a bite from one vector infected with different 
genotypes; reinfection with a single genotype as the result of multiple bites from vectors 
singly infected with the same genotype; or reinfection with different genotypes as the result 
of multiple bites from vectors harbouring different genotypes (Figure 1). The complexity of 
these interactions may be extensive, with 89 different genotypes of T. cruzi isolated from 
humans in Bolivia alone [18]. 
How might these interactions affect the progression of CD, patient prognosis and clinical 
management? Reinfection can result in a more severe disease progression developing, 
exacerbating the consequences of infection in terms of inflammation, fibrosis and/or 
necrosis within host organs [19, 20]. By contrast, other studies have found an abatement of 
host effects with reinfection, a phenomenon described as immune protection [21]. Mixed 
infections may also have variable effects on disease progression, given that growth patterns 
and phenotypic behaviour of one genotype are potentially altered by the presence of 
another T. cruzi genotype within the host [22]. Complications associated with multiple 
infections may also adversely affect patient outcome and the success of therapeutic 
interventions [23], with genotypes varying in their sensitivity to benznidazole [24]. 
Additionally, the genotypes of parasites circulating in the host bloodstream can differ from 
those present within host organs, leading to difficulties in diagnosing mixed infections [25, 
26] and the potential for underreporting. Despite these previous studies, however, we lack a 
clear understanding of the effects of genetic diversity in mixed infection and reinfection 
scenarios, or whether the order of exposure in mixed reinfections has the potential to alter 
disease progression depending on which genotype establishes infection first. 
Mouse models for CD are commonly utilised for investigating drug efficacy and the host 
immune response to infection, and previous work in our laboratory has used mice to study 
complications to CD arising from reinfection and immune suppression. In this study, we 
aimed to investigate the effects of simultaneous mixed infections, and reinfections with the 
same or different genotypes of T. cruzi, on disease progression in mice using isolates of T. 
cruzi from two different DTUs; TcI (C8 clone 1) and TcIV (10R26). We hypothesised firstly, 
that simultaneous mixed infections and reinfections with these isolates would exacerbate 
host morbidity and mortality compared to single infections with one isolate; and further, 
that the impact of reinfections would be mediated by the order in which isolates were 
introduced into the host. 
1.2 Materials and Methods 
1.2.1 Experimental design 
Seven treatment groups made up of either 10 or 15 Swiss mice per group were infected by 
intraperitoneal (i.p) injection with different combinations of T. cruzi isolates (Table 1). To 
compare the effects of single infections and mixed infections on the host, two singly 
infected treatment groups (one group infected with C8 clone 1 and the other infected with 
10R26); and one mixed infection group (animals infected with both C8 clone 1 and 10R26) 
were used. In order to investigate reinfections and any effects associated with the order of 
exposure on the host, four treatment groups were used: C8 clone 1 infected and 10R26 
reinfected; 10R26 infected and C8 clone 1 reinfected; C8 clone 1 infected and reinfected; 
and 10R26 infected and reinfected. 
Where relevant, reinfection was carried out on day 14 by i.p. injection. Fifty thousand tissue 
culture derived trypomastigotes (TCDT) of the relevant isolate was utilised for each 
inoculant, and in the case of the mixed infection treatment group, 50,000 TCDT of each 
isolate was inoculated. Previous studies on these isolates in this laboratory demonstrated 
no significant effect of inoculant size (between 25,000 and 100,000 TCDT) on host morbidity 
or disease outcome (data not shown). To reduce the number of mice required, we did not 
utilise sham-treated control groups; previous studies have followed a similar protocol for 
intraperitoneal (i.p) injection [27-29], reinfection [20, 30, 31] and 
cyclophosphamide/immune suppression [32, 33], as the handling involved in these 
treatments is not expected to alter disease progression. 
1.2.2 Parasites 
The phenotypic characteristics of the two isolates that were utilised in this study are not 
known, but they are phylogenetically distinct (C8 clone 1 from the TcI DTU and 10R26 from 
the TcIV DTU) and both have relevance to CD within humans [34, 35]. The C8 clone 1 isolate 
was obtained from a vector within the domestic cycle, and 10R26 was isolated from a 
monkey in the sylvatic cycle. 
Tissue culture derived trypomastigotes (TCDT) were used for the inoculation of all 
experimental animals. The C8 clone 1 and 10R26 clones were received as epimastigotes, 
shock thawed, and grown in plates containing 25 g/L Liver Infusion Tryptose medium (BD 
Difco, France) supplemented with 4 g/L NaCl (Sigma-Aldrich, USA), 2 g/L D-glucose (Sigma-
Aldrich, USA), 0.4 g/L KCl (UniVar, New Zealand), 3.15 g/L Na2HPO4 (Chemsupply, Australia), 
1 ml of 25 mg/ml haemin (Sigma-Aldrich, USA) prepared in 1 M NaOH (Sigma-Aldrich, USA) 
and 10% heat-inactivated foetal bovine serum (Sigma-Aldrich, Australia) at 27°C in 5% CO2 
to encourage metacyclogenesis. L6 cells were used to propagate TCDT for inoculation, and 
were grown in Roswell Park Memorial Institute-1640 medium (Sigma-Aldrich, Australia) 
supplemented with 10% heat-inactivated foetal bovine serum (Sigma-Aldrich, Australia) at 
37°C in 5% CO2. Following metacyclogenesis, mammalian cell monolayers were infected by 
the addition of metacyclic trypomastigote cultures and incubated at 37°C in 5% CO2. After 
24 hours, culture supernatants were replaced, with subsequent cultures created every 3-4 
days by the addition of trypomastigotes from healthy cultures to fresh mammalian cell 
cultures. For animal work, parasites were enumerated prior to infection and adjusted to a 
concentration of 5 x 105 trypomastigotes/ml or 1 x 106 trypomastigotes/ml. 
1.2.3 Animal monitoring and measurement 
Ninety five Swiss outbred mice were received from the Animal Resources Centre (Canning 
Vale, Australia). During the experiment, water and chow were available ad libitum within a 
temperature controlled room on a 12 hour light/dark cycle. Enumeration of parasitaemia 
was carried out by fresh blood examination by microscopy of blood obtained from tail 
venepuncture every second day, up to 30 days post infection (p.i.). Animals were weighed 
(to the nearest gram) prior to infection and prior to blood sample collections. Daily 
monitoring was carried out prior to sampling, and noticeable changes in posture, activity, 
gait, respiratory patterns, hydration, body condition and hair were documented using a 
grading system: 0 (no obvious deviation from normal); 1 (slight possible abnormality); 2 
(definite change from normal, but not marked); or 3 (a gross change from normal). The sum 
of these scores generated a body condition score for each animal per monitored day over 
the experimental period. An acute reduction in body condition was observed in a subset of 
reinfected animals during the experiment; these animals were immediately euthanized and 
counted as ‘mortalities’ for analysis. Cardiac punctures were carried out where possible and 
tissue samples taken from these ‘mortalities’. On day 30, all remaining mice were 
euthanized, cardiac punctures carried out and tissue samples taken. Tissue samples 
harvested included colon, heart, both kidneys, liver, skeletal muscle and spleen. Organ 
samples were divided in two portions, with one portion fixed and stored in 100% ethanol for 
PCR analysis, and the other fixed and stored in 10% formalin for histological analysis. 
1.2.4 Histopathology 
Formalin fixed samples of kidneys, skeletal muscle, heart, liver, spleen and colon were 
sectioned (4µm thick) and stained with Hematoxylin and Eosin. Slides and tissues were 
evaluated and analyzed in a single-blind study carried out by one pathologist, based on the 
method of Gruendling et al. [36]. For each of the tissues evaluated, the parameters included 
tissue parasitism, inflammatory process (intensity, type, and distribution), and tissue 
reaction (necrosis, haemorrhage). Tissue parasitism was evaluated at 400x magnification 
based on the presence or absence of amastigote nests and classified as: 0 (absent); 1 (mild, 
1-5 nests); 2 (moderate, 6-10 nests); or 3 (severe, >10 nests). The inflammatory process was 
evaluated for intensity (number of inflammatory cells at 400x magnification) and classified 
as: 1 (mild, 10-25 cells); 2 (moderate, 26-50 cells); or 3 (severe, >50 cells). Tissues were 
additionally evaluated for necrosis and haemorrhage, and were classified as 1 (mild, 0-30% 
affected); 2 (moderate, 30-55% affected) or 3 (severe, >55% affected). A total pathology 
score was created for each animal by summing scores for inflammatory response, necrosis 
and haemorrhage over all tissues. 
  
1.2.5 PCR and DNA sequencing 
DNA extraction was carried out as per kit instructions (Qiagen, Germany) and DNA was 
stored at -20°C until analysis was carried out. Positive and negative controls were utilised in 
each DNA extraction and PCR reaction. Initially, PCR was carried out using Trypanosoma 
cruzi specific primers (TCZF 5’ GCT CTT GCC CAC AMG GGT GC 3’ and TCZR 5’ CCA AGC AGC 
GGA TAG TTC AGG 3’) that detect an 188bp fragment of DNA. Each reaction tube contained 
10x reaction buffer (670mM Tris-HCl, 166mM (NH4)2SO4, 4.5% Triton X-100, 2 mg/ml 
Gelatin), 0.04% cresol red, 2mM MgCl2, 1.25μM of each primer, 0.5μM of each dNTP and 
0.5U Taq polymerase. 
The generic primer set used to amplify T. cruzi satellite DNA was used to confirm the 
presence or absence of T. cruzi DNA within different tissues, with bands of expected size 
(188bp) selected, purified and prepared for sequencing submission. Bands were cut from 
electrophoresis gels and DNA from the bands was extracted [37]. DNA was purified using 
Agencourt AMPure PCR Purification system (manufacturer’s instructions) and sequenced 
using an ABI PrismTM Terminator Cycle Sequencing kit (Applied Bio-systems, USA) on an 
Applied-Biosystem 3730 DNA Analyzer. Sequences for all bands of the expected size were 
confirmed as T. cruzi satellite DNA by BLAST search. 
In order to differentiate between the two isolates within mixed infections, amplification of 
the intergenic region of the T. cruzi mini-exon genes was carried out using TCC (5’ 
CCCCCCTCCCAGGCCACACTG 3’), TCI (5’ GTGTCCGCCACCTCCTTCGGGCC 3’) and TCII (5’ 
CCTGCAGGCACACGTGTGTGTG 3’) primers as previously published [38], and amplification of 
the 24Sα rDNA region was carried out using D71 (5’ AAGGTGCGTCGACAGTGTGG 3’) and D72 
(5’ TTTTCAGAATGGCCGAACAGT 3’) primers. Each reaction tube contained 10x reaction 
buffer (670 mM Tris-HCl, 166 mM (NH4)2SO4, 4.5% Triton X-100, 2 mg/ml gelatin), 0.04% 
cresol red, 0.5 mM MgCl2, 0.4 μM of each primer, 0.2 mM of each dNTP and 2.5 U Taq 
polymerase. PCR Samples were incubated at 94°C for 5 minutes prior to undergoing 50 
cycles at 94°C for 20 seconds, 60°C for 10 seconds and 72°C for 30 seconds, followed by a 
final elongation at 72°C for 7 minutes. Amplified bands were visualised on a 2.0% agarose 
gel containing 2% SYBR safe using a dark-reader trans-illuminator. 
The mini-exon primer set TCC, TCI and TCII has been utilised previously to discriminate 
between TcI and TcIV T. cruzi isolates, however this primer set gave no amplification for 
10R26 control DNA, a phenomenon that has previously been documented [39]. 
Subsequently, D71 and D72 primers [38, 40] detecting the 24Sα rDNA, were utilised and 
although this primer set could successfully differentiate between the TcI and TcIV DTU single 
controls, when the two controls were mixed only one band was detected, suggesting the 
preferential amplification of DNA of one of the DTUs over the other. Given this limitation, 
the confirmation of which of the two isolates was present within host organs within mixed 
infection scenarios was unable to be determined. Given the unequal distribution of 
parasites present within host tissues it was not feasible to determine the parasite load 
within host tissues and additionally the use of quantitative PCR (qPCR) was outside of the 
scope of these studies. 
1.2.6 Data analysis 
The data were analysed as two separate experiments: first, comparing the two single 
infection groups with the simultaneous mixed infection group; and second, comparing the 
single infection groups with the four different reinfection groups. Mortality rates were 
compared among treatments by a contingency 2 analysis. If a significant effect was 
identified, multiple pairwise comparisons were carried out using a Bonferroni correction, to 
identify which treatments differed from each other. Survival times were compared among 
treatments by the Kaplan–Meier method, with a 2 approximation to the log rank test. Final 
body weight, pathology score and the number of organs infected by T. cruzi (as determined 
by PCR) were compared among treatments by one-way analysis of variance, followed by 
Tukey’s HSD test for multiple comparisons. The residuals from all of these analyses were 
normally distributed. The residuals from an initial analysis of body condition score were 
markedly non-normal, and comparisons among treatments for this variable were instead 
made using a non-parametric Kruskal-Wallis test, followed by pairwise Wilcoxon tests for 
multiple comparisons, using a Bonferroni correction.  
Tissue tropism in the isolates was examined by comparing the distribution among tissues for 
each isolate in the two single infection groups. These data were analysed using a 
generalised linear model, treating presence or absence of parasites (as determined from 
PCR) as a binomial response variable with a logit link function, with isolate, tissue type, and 
their interaction as factors. 
All statistical tests were carried out using the software JMP 10.0 (SAS Institute Inc., Cary, NC, 
USA) and survivability plots were constructed using GraphPad Prism 5. 
1.3 Results 
1.3.1 Single infections and mixed isolate infections 
There were no significant differences in the body weight or condition score of animals 
assigned to the different treatment groups prior to infection. No mortalities were observed 
in either the C8 clone 1 or 10R26 singly infected, or C8 clone 1 + 10R26 mixed infected 
animals, nor did they differ in body weight or condition at the end of the experiment. There 
were significant differences among treatments, however, in pathology scores (F2,37 = 4.67, P 
= 0.02), and number of organs infected (F2,36 = 7.96, P = 0.001). Pathology scores were 
significantly greater for animals singly infected with C8 clone 1, or mixed infected with C8 
clone 1 + 10R26, than for animals singly infected with 10R26 (Figure 1.2). The number of 
infected organs was greater for animals mixed infected with C8 clone 1 + 10R26 than for 
those singly infected with either clone (Figure 1.3 and Table 2). Although there were 
differences among tissues in the probability of infection (26= 77.5, P < 0.0001) for the two 
single infection groups, there were no significant effects of isolate (21= 1, P = 0) or isolate x 
tissue interaction (26= 6.4, P = 0.4). 
1.3.2 Single infections and reinfections 
There were no significant differences in the body weight or condition score of animals 
assigned to the different treatment groups prior to infection. Following reinfection, 
spontaneous deaths were observed in all reinfection groups, with an overall mortality rate 
of 63.6% (Figure 1.4). There were significant differences among treatment groups in 
mortality (25 = 38.97, P < 0.0001) and survival time (25 = 29.24, P < 0.0001), with all 
reinfection groups differing significantly from single infection groups (P < 0.05, with the 
Bonferroni), but not among themselves. There were also significant differences among 
treatment groups in final body weight (F5,74 = 2.79, P = 0.02), body condition (25 = 28.38, P < 
0.0001), pathology score (F5,73 = 3.47, P = 0.01) and the number of infected organs (F5,73 = 
3.89, P = 0.003). Pairwise comparisons indicated that body weight and condition were 
significantly less in all reinfection groups than in single infection groups, but did not differ 
among themselves. Pathology scores were significantly greater for animals singly infected 
with C8 clone 1 than those singly infected with 10R26, but did not differ among reinfection 
groups or between reinfection and single infection groups (Figure 1.5), while the number of 
infected organs was greater for animals infected and reinfected with C8 clone 1 than for C8 
clone 1 singly infected animals or for those infected with C8 clone 1 and reinfected with 
10R26 (Figure 1.6 and Table 3). 
  
1.4 Discussion 
The results from this study have partially confirmed our initial hypotheses. Although we 
found no increase in host morbidity or mortality as a result of a simultaneous mixed 
infection with two genetically different isolates of T. cruzi, there was evidence that the 
parasite was more widely disseminated among host tissues. Reinfection, by contrast, led to 
a marked increase in both morbidity and mortality, regardless of which of the two isolates 
were involved. 
1.4.1 Effects of reinfection 
Previous studies exploring reinfections have provided contrasting results. On the one hand, 
the generation of a parasitaemia following initial infection, with subsequent infections 
generating lower [21] or no parasitaemias in mice, and the observation of no significant 
increase in tissue damage in reinfected dogs independent of isolates utilised [41], are 
indicative of host immune protection. Conversely, other studies investigating reinfection 
have demonstrated a failure to protect mice [42], with the observation of an increased 
parasitaemia [30] and an increase in the severity of cardiac alterations and disease 
progression [20, 43]. Subsequently, these alterations may lead to death of the host [31]. 
The dichotomy of host effects observed following reinfection highlights the complexity of 
disease progression and the way in which it may be altered due to complications to 
infection. Much of the frustration surrounding CD research is due to the heterogeneity of 
symptoms and disease progression observed across the study of different T. cruzi strains 
and hosts [44]. This genetic heterogeneity means that dissimilar outcomes from reinfection 
experiments may reflect differences in parasite virulence or in the host immune response to 
the different parasite genotypes utilised. While the use of reference or highly utilised 
genotypes such as the Y [31, 43], Tulahuen [20] and Colombian strains [45] in previous 
reinfection studies was useful in order for comparisons to be drawn between studies, more 
studies involving diverse and previously uncharacterised genotypes are also required to 
expand our knowledge. 
In the current study, all four reinfection scenarios produced a sudden and rapid 
deterioration in body condition 14 days p.i., sufficient to require immediate euthanasia. As 
far as we are aware, only one previous study has found spontaneous deaths, where 
unexplained deaths were acutely observed following T. cruzi reinfection in mice [31]. The 
reinfection scenarios in this study by Andrade et al. [31] involved the use of single 
Colombian infected controls, animals re-infected with two different isolates in separate 
inoculants (Colombian, then 21SF; or Colombian, then Y strain); and animals reinfected with 
three different isolates in separate inoculants (Colombian, then 21SF, then Y strain; or 
Colombian, then Y, then 21SF). Because there was no mixed infection or simultaneous 
infection baseline group, it is unclear whether the challenge of reinfection or the exposure 
to multiple strains was the cause of the spontaneous deaths observed, or whether it was in 
fact an unrelated anomaly. In the current study, we were able to determine, firstly, that 
simultaneous mixed infections did not produce acute morbidity and, secondly, that 
reinfection did produce acute morbidity, regardless of whether it involved one or two 
genetically different isolates of the parasite, and regardless of the order in which the 
isolates infected the host. 
Andrade et al. [31] provided no explanation for the spontaneous deaths they observed, 
however we propose that these may have been due to cumulative effects of tissue damage 
by isolates that differed in their tissue tropism and pathogenicity and/or an aggravated 
hypersensitivity reaction. In the current study, the results would suggest that a 
hypersensitivity reaction was a more likely cause, because of the absence of any synergistic 
effect from infection with different isolates, either simultaneously or separately. Cardiac 
alterations and involvement is the leading known proximate cause of acute or sudden 
deaths associated with CD [46-48], and there was evidence of enhanced myocardial 
pathology following reinfection with three isolates by Andrade et al. [31]. In the current 
study however, there was no pathological evidence to support cardiac alterations as the 
cause of death. Another known cause of CD-related sudden deaths is severe 
meningoencephalitis [49, 50] however because brain pathology was not investigated we 
cannot comment on the likelihood of this occurring, nor can we rule out another unknown 
cause for this host response. 
1.4.2 Effects of multiple infection 
In contrast to results from reinfection studies, simultaneous mixed infections with the C8 
clone 1 and 10R26 isolates had no observable effects on host pathology. Although no 
parasitaemia was observed, nor were there any differences in host survival or pathological 
response between mice receiving single-isolate or mixed infections, we found that mixed 
isolate T. cruzi hosts demonstrated a more disseminated infection (as determined by PCR) 
compared to singly infected animals. Considering the marked differences observed in tissue 
tropism across strains [51-53], if the tissue tropism of the infecting isolates differ, than a 
more disseminated infection is possible. Further, tissue tropism may be altered by parasite-
parasite interactions within mixed infections [54], therefore potentially altering the 
dissemination of pathology. However, we found no differences in tissue tropism across the 
singly infected C8 clone 1 or 10R26 groups, thus not supporting this theory. There is also the 
potential for the increased dissemination of infection to be due to the increased inoculant 
size due to multiple exposures, however previous research carried out in our laboratory 
demonstrated no observable difference in the pathology, host outcome or disease 
progression for individuals that received higher inoculants (data not shown). 
Previous research investigating T. cruzi experimental mixed infections is limited, however 
one study reported that their mixed infected group demonstrated a severe inflammatory 
infiltrate, compared to singly infected groups [26]. Interestingly, another study reported 
that within TcIII/TcV, TcIII/TcVI, and TcV/TcVI mixed infected groups, the presence of both 
isolates was not detected within the same host tissue [54], perhaps resulting in an overall 
increase in the dissemination of infection. Although we were unable to confirm which 
isolate was present in each host tissue, it is possible that the increase in number of organs 
infected with T. cruzi was due to competition among isolates. This presents an important 
area for future research. There has been much interest in within-host competition among 
parasite strains, particularly if those strains differ in virulence. Both theoretical [55, 56] and 
empirical [57] studies suggest that more virulent parasite strains will out-compete less 
virulent strains, although, as far as we are aware, this has not been tested in T. cruzi. 
The results of this study highlight the significance that mixed infections may have on host 
survivability and disease progression in terms of the dissemination of disease throughout 
the host, which can affect disease outcome and the success of therapeutic interventions 
[23, 58]. Mixed infections also create additional complications for drug discovery work [58], 
and may explain contradictory results obtained from human treatments [59]. Current 
literature on drug efficacy and treatment outcomes for mixed (and also reinfection) 
scenarios are incredibly limited, given the potential ramifications to the treatment of CD. 
Further research in this area may provide useful information on the effects of mixed 
infection and lead to crucial improvements in treatment options. 
1.4.3 Differences between isolates 
Mice that were singly infected with C8 clone 1 had significantly greater mean pathology 
scores than those that were singly infected with 10R26. Further, animals infected and 
reinfected with C8 clone 1 had a significantly greater number of organs PCR positive 
compared to mice singly infected with C8 clone1, while 10R26 infected and reinfected 
animals demonstrated no such difference to mice singly infected with 10R26. These results 
suggest that the C8 clone 1 isolate has a greater propensity to infect and cause damage 
within hosts than 10R26. 
Greater virulence has been associated with the presence of a parasitaemia in previous 
studies [28, 60, 61]. Within blood samples in the current study, C8 clone 1 singly infected 
animals demonstrated an absence of T. cruzi DNA, however T. cruzi DNA was detected in 
mixed C8 clone 1 + 10R26 infections, C8 clone 1 infected and reinfected, C8 clone1 infected 
and 10R26 reinfected, and 10R26 infected and C8 clone 1 reinfected scenarios. Additionally, 
T. cruzi was not detected in blood samples from animals infected with, and infected and 
reinfected with 10R26. Although discrimination between isolates within mixed infection 
scenarios was not possible, these results suggest that C8 clone 1 is more readily detected in 
the blood within mixed infections than 10R26, supporting the suggested greater virulence of 
the C8 clone 1 isolate. 
1.5 Conclusions 
Reinfection with T. cruzi was able to alter host survival, with significantly increased 
pathological response and mortality rates observed within reinfected hosts compared to 
their singly exposed counterparts. An acute and fatal response that has only been 
documented once previously was observed in a large number of reinfected hosts. 
Simultaneous infection with two isolates (i.e. mixed infection or polyparasitism) was not 
associated with increased host morbidity or mortality, although it did generate a more 
disseminated infection, with multiply infected hosts displaying a greater number of organs 
containing T. cruzi than their singly infected counterparts. Although the host’s response to 
these two phenomena was vastly different, both have the potential to alter the way in 
which disease is managed. In a clinical context, within endemic areas there is a high risk of 
both multiple exposures to T. cruzi, with a very high prevalence of infection in vectors [9, 10] 
and of exposure to different genotypes, with vectors commonly found to be harbouring 
mixed T. cruzi infections [17]. Although the extent to which our findings with mice can be 
generalised to human hosts is unclear, there is an urgent need for more investigation of the 
clinical consequences of reinfections and mixed infections of T. cruzi. 
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Figure 1.1: A conceptual illustration of the ways by which a host may be infected and/or 
reinfected when different T. cruzi genotypes are circulating in a vector population. For 
simplicity, four infection scenarios are illustrated, with only two genotypes and two different 
time frames of infection considered. A) A single infection transmitted from one vector 
harbouring a single parasite genotype (vector A). B) A mixed infection with genotypes 1 and 
2 transmitted simultaneously from a vector harbouring both genotypes (vector B). C) 
Infection and reinfection with genotype 1 where the host is bitten on more than one occasion 
by a vector harbouring a single genotype (vector A). D) Infection with genotype 1 and 
reinfection with genotype 2, where the host is bitten on more than one occasion by vectors 
each harbouring single infections (vectors A and C). 
 
 
Figure 1.2: Pathology scores for animals with single and mixed infections of T. cruzi. Mean 
pathology scores, with standard error bars, for C8 clone 1, 10R26, and mixed C8 clone 1 + 
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cruzi. T. Mean number of organs positive for T. cruzi DNA, with standard error bars, from C8 
clone 1, 10R26 and mixed C8 clone 1 + 10R26 infected animals. Treatment groups not 
connected by a letter are significantly different. 
 
Figure 1.4: Survival rates for hosts with single infections and reinfections with different 
combinations of T. cruzi isolates. Percent survival for C8 clone 1 and 10R26 infected baseline 
groups; and mixed C8 clone 1 infected and 10R26 reinfected, 10R26 infected and C8 clone 1 
reinfected, C8 clone 1 infected and reinfected, and 10R26 infected and reinfected treatment 
groups. Refer to Table 2 for details of infections. 
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Figure 1.5: Pathology scores for animals with single infections and reinfections with different 
combinations of T. cruzi isolates. Mean pathology scores, with standard error bars, for C8 
clone 1 and 10R26 infected baseline groups; and mixed C8 clone 1 infected and 10R26 
reinfected, 10R26 infected and C8 clone 1 reinfected, C8 clone 1 infected and reinfected, 
and 10R26 infected and reinfected treatment groups. Treatment groups not connected by a 
letter are significantly different. 
Figure 1.6: Number of organs PCR positive for animals with single infections and reinfections 
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standard error bars, for C8 clone1, 10R26 infected baseline groups; and mixed C8 clone 1 
infected and 10R26 reinfected, 10R26 infected and C8 clone 1 reinfected, C8 clone 1 
infected and reinfected, and 10R26 infected and reinfected treatment groups. Treatment 




Table 1: Infection combinations for the 7 treatment groups of T. cruzi infected animals. 
Singly, mixed and reinfected treatment groups infected with T. cruzi. Treatment = treatment 
group, N = number of mice per group. 
Treatment N Initial infection (day 0) Reinfection (day 14) 
C8 clone 1  15 C8 clone 1 N/A 
10R26 10 10R26 N/A 
10R26+C8 clone 1 15 10R26 and C8 clone 1 N/A 
C8 clone 1 10R26 15 C8 clone 1 10R26 
10R26  C8 clone 1 15 10R26 C8 clone 1 
C8 clone 1  C8 clone 1 15 C8 clone 1 C8 clone 1 
10R26  10R26 10 10R26 10R26 
 
Table 2: T. cruzi DNA detected within host blood and organs of mice from different 
treatment groups. B = blood; C= colon; H = heart; K = kidney; L = liver; SM = skeletal muscle; 
S = spleen; * = one exposure to T. cruzi infection. 
Treatment group B C H K L SM S 
C8 clone 1 * 0/14 15/15 6/15 10/15 12/15 13/15 4/15 
10R26 * 0/10 9/10 8/10 6/10 7/10 10/10 7/10 
10R26 + C8 clone1 * 2/15 14/15 12/15 13/15 14/15 15/15 11/15 
 
Table 3: T. cruzi DNA detected within host blood and organs of mice from different 
treatment groups. B = blood; C= colon; H = heart; K = kidney; L = liver; SM = skeletal muscle; 
S = spleen; * = one exposure; ** = two exposures to T. cruzi infection. For reinfected 
animals, blood samples were taken where possible. 
Treatment group B C H K L SM S 
C8 clone 1 * 0/14 15/15 6/15 10/15 12/15 13/15 4/15 
10R26 * 0/10 9/10 8/10 6/10 7/10 10/10 7/10 
C8 Clone 1  10R26 ** 6/13 12/15 6/15 7/15 15/15 13/15 10/15 
10R26  C8 clone 1 ** 9/14 11/15 12/15 11/15 14/15 11/15 9/15 
C8 clone 1  C8 clone 1 ** 2/6 15/15 14/15 14/15 15/15 14/15 14/15 
10R26  10R26 ** 0/4 8/10 8/10 6/10 8/10 9/10 9/10 
 
